Simultaneous and high-throughput quantitation of urinary tetranor PGDM and tetranor PGEM by online SPE-LC-MS/MS as inflammatory biomarkers
Quantitation of urinary tetranor PGDM or tetranor PGEM (tPGDM and tPGEM) in the past was performed separately using off‐line SPE LC–MS/MS methods. The manual SPE procedure is generally time‐consuming and cost‐ineffective. In addition, simultaneous quantitation of tPGDM and tPGEM is favorable yet ver...
Saved in:
Published in | Journal of mass spectrometry. Vol. 46; no. 7; pp. 705 - 711 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Chichester, UK
John Wiley & Sons, Ltd
01.07.2011
Wiley |
Subjects | |
Online Access | Get full text |
ISSN | 1076-5174 1096-9888 1096-9888 |
DOI | 10.1002/jms.1941 |
Cover
Abstract | Quantitation of urinary tetranor PGDM or tetranor PGEM (tPGDM and tPGEM) in the past was performed separately using off‐line SPE LC–MS/MS methods. The manual SPE procedure is generally time‐consuming and cost‐ineffective. In addition, simultaneous quantitation of tPGDM and tPGEM is favorable yet very challenging because of the similar chemical structures and identical MRM transitions. This work describes the development and validation of a high‐throughput online SPE‐LC–MS/MS method, allowing simultaneous and high‐throughput measurement of tPGDM and tPGEM in human urine. The reportable range of the assay was 0.2–40 ng/ml for tPGDM and 0.5–100 ng/ml for tPGEM. Intra‐ and inter‐assay precision and accuracy determined using quality control samples were all within acceptable ranges (% CV and % Bias < 15%). Tetranor PGDM was stable under all tested conditions while tPGEM was stable at 4 °C and after three F/T cycles but not stable at room temperature for 24 h (recovery below 80%). The assay was applied to measure urinary tPGDM and tPGEM among healthy volunteers, smokers and COPD patients. Significantly higher urinary levels of both tPGDM and tPGEM were observed in COPD patients than those of non‐smoking healthy volunteers. These results demonstrated that the high‐throughput online SPE‐LC–MS/MS assay provides sensitive, reproducible and accurate measurement of urinary tPGDM and tPGEM as biomarkers for assessing inflammatory diseases such as COPD. Copyright © 2011 John Wiley & Sons, Ltd. |
---|---|
AbstractList | Quantitation of urinary tetranor PGDM or tetranor PGEM (tPGDM and tPGEM) in the past was performed separately using off‐line SPE LC–MS/MS methods. The manual SPE procedure is generally time‐consuming and cost‐ineffective. In addition, simultaneous quantitation of tPGDM and tPGEM is favorable yet very challenging because of the similar chemical structures and identical MRM transitions. This work describes the development and validation of a high‐throughput online SPE‐LC–MS/MS method, allowing simultaneous and high‐throughput measurement of tPGDM and tPGEM in human urine. The reportable range of the assay was 0.2–40 ng/ml for tPGDM and 0.5–100 ng/ml for tPGEM. Intra‐ and inter‐assay precision and accuracy determined using quality control samples were all within acceptable ranges (% CV and % Bias < 15%). Tetranor PGDM was stable under all tested conditions while tPGEM was stable at 4 °C and after three F/T cycles but not stable at room temperature for 24 h (recovery below 80%). The assay was applied to measure urinary tPGDM and tPGEM among healthy volunteers, smokers and COPD patients. Significantly higher urinary levels of both tPGDM and tPGEM were observed in COPD patients than those of non‐smoking healthy volunteers. These results demonstrated that the high‐throughput online SPE‐LC–MS/MS assay provides sensitive, reproducible and accurate measurement of urinary tPGDM and tPGEM as biomarkers for assessing inflammatory diseases such as COPD. Copyright © 2011 John Wiley & Sons, Ltd. Quantitation of urinary tetranor PGDM or tetranor PGEM (tPGDM and tPGEM) in the past was performed separately using off-line SPE LC-MS/MS methods. The manual SPE procedure is generally time-consuming and cost-ineffective. In addition, simultaneous quantitation of tPGDM and tPGEM is favorable yet very challenging because of the similar chemical structures and identical MRM transitions. This work describes the development and validation of a high-throughput online SPE-LC-MS/MS method, allowing simultaneous and high-throughput measurement of tPGDM and tPGEM in human urine. The reportable range of the assay was 0.2-40 ng/ml for tPGDM and 0.5-100 ng/ml for tPGEM. Intra- and inter-assay precision and accuracy determined using quality control samples were all within acceptable ranges (% CV and % Bias < 15%). Tetranor PGDM was stable under all tested conditions while tPGEM was stable at 4 °C and after three F/T cycles but not stable at room temperature for 24 h (recovery below 80%). The assay was applied to measure urinary tPGDM and tPGEM among healthy volunteers, smokers and COPD patients. Significantly higher urinary levels of both tPGDM and tPGEM were observed in COPD patients than those of non-smoking healthy volunteers. These results demonstrated that the high-throughput online SPE-LC-MS/MS assay provides sensitive, reproducible and accurate measurement of urinary tPGDM and tPGEM as biomarkers for assessing inflammatory diseases such as COPD. Quantitation of urinary tetranor PGDM or tetranor PGEM (tPGDM and tPGEM) in the past was performed separately using off-line SPE LC-MS/MS methods. The manual SPE procedure is generally time-consuming and cost-ineffective. In addition, simultaneous quantitation of tPGDM and tPGEM is favorable yet very challenging because of the similar chemical structures and identical MRM transitions. This work describes the development and validation of a high-throughput online SPE-LC-MS/MS method, allowing simultaneous and high-throughput measurement of tPGDM and tPGEM in human urine. The reportable range of the assay was 0.2-40 ng/ml for tPGDM and 0.5-100 ng/ml for tPGEM. Intra- and inter-assay precision and accuracy determined using quality control samples were all within acceptable ranges (% CV and % Bias < 15%). Tetranor PGDM was stable under all tested conditions while tPGEM was stable at 4 °C and after three F/T cycles but not stable at room temperature for 24 h (recovery below 80%). The assay was applied to measure urinary tPGDM and tPGEM among healthy volunteers, smokers and COPD patients. Significantly higher urinary levels of both tPGDM and tPGEM were observed in COPD patients than those of non-smoking healthy volunteers. These results demonstrated that the high-throughput online SPE-LC-MS/MS assay provides sensitive, reproducible and accurate measurement of urinary tPGDM and tPGEM as biomarkers for assessing inflammatory diseases such as COPD.Quantitation of urinary tetranor PGDM or tetranor PGEM (tPGDM and tPGEM) in the past was performed separately using off-line SPE LC-MS/MS methods. The manual SPE procedure is generally time-consuming and cost-ineffective. In addition, simultaneous quantitation of tPGDM and tPGEM is favorable yet very challenging because of the similar chemical structures and identical MRM transitions. This work describes the development and validation of a high-throughput online SPE-LC-MS/MS method, allowing simultaneous and high-throughput measurement of tPGDM and tPGEM in human urine. The reportable range of the assay was 0.2-40 ng/ml for tPGDM and 0.5-100 ng/ml for tPGEM. Intra- and inter-assay precision and accuracy determined using quality control samples were all within acceptable ranges (% CV and % Bias < 15%). Tetranor PGDM was stable under all tested conditions while tPGEM was stable at 4 °C and after three F/T cycles but not stable at room temperature for 24 h (recovery below 80%). The assay was applied to measure urinary tPGDM and tPGEM among healthy volunteers, smokers and COPD patients. Significantly higher urinary levels of both tPGDM and tPGEM were observed in COPD patients than those of non-smoking healthy volunteers. These results demonstrated that the high-throughput online SPE-LC-MS/MS assay provides sensitive, reproducible and accurate measurement of urinary tPGDM and tPGEM as biomarkers for assessing inflammatory diseases such as COPD. Quantitation of urinary tetranor PGDM or tetranor PGEM (tPGDM and tPGEM) in the past was performed separately using off-line SPE LC-MS/MS methods. The manual SPE procedure is generally time-consuming and cost-ineffective. In addition, simultaneous quantitation of tPGDM and tPGEM is favorable yet very challenging because of the similar chemical structures and identical MRM transitions. This work describes the development and validation of a high-throughput online SPE-LC-MS/MS method, allowing simultaneous and high-throughput measurement of tPGDM and tPGEM in human urine. The reportable range of the assay was 0.2-40 ng/ml for tPGDM and 0.5-100 ng/ml for tPGEM. Intra- and inter-assay precision and accuracy determined using quality control samples were all within acceptable ranges (% CV and % Bias < 15%). Tetranor PGDM was stable under all tested conditions while tPGEM was stable at 4 ?C and after three F/T cycles but not stable at room temperature for 24 h (recovery below 80%). The assay was applied to measure urinary tPGDM and tPGEM among healthy volunteers, smokers and COPD patients. Significantly higher urinary levels of both tPGDM and tPGEM were observed in COPD patients than those of non-smoking healthy volunteers. These results demonstrated that the high-throughput online SPE-LC-MS/MS assay provides sensitive, reproducible and accurate measurement of urinary tPGDM and tPGEM as biomarkers for assessing inflammatory diseases such as COPD. |
Author | Lin, Zhaosheng Huang, Jeffrey T. J. Zhang, Yizhong Muirhead, David Zhang, Guodong Clarke, Philip A. Steenwyk, Rick C. Takahashi, Eddie |
Author_xml | – sequence: 1 givenname: Yizhong surname: Zhang fullname: Zhang, Yizhong organization: Pfizer, Inc., Groton, CT 06340, USA – sequence: 2 givenname: Guodong surname: Zhang fullname: Zhang, Guodong organization: Pfizer, Inc., Groton, CT 06340, USA – sequence: 3 givenname: Philip A. surname: Clarke fullname: Clarke, Philip A. organization: Pfizer, Inc., Groton, CT 06340, USA – sequence: 4 givenname: Jeffrey T. J. surname: Huang fullname: Huang, Jeffrey T. J. organization: Pfizer, Inc., Groton, CT 06340, USA – sequence: 5 givenname: Eddie surname: Takahashi fullname: Takahashi, Eddie organization: Pfizer, Inc., Groton, CT 06340, USA – sequence: 6 givenname: David surname: Muirhead fullname: Muirhead, David organization: Pfizer, Inc., Groton, CT 06340, USA – sequence: 7 givenname: Rick C. surname: Steenwyk fullname: Steenwyk, Rick C. organization: Pfizer, Inc., Groton, CT 06340, USA – sequence: 8 givenname: Zhaosheng surname: Lin fullname: Lin, Zhaosheng email: joe-zhaosheng.lin@pfizer.com organization: Pfizer, Inc., Groton, CT 06340, USA |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24332242$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21706677$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kV2P1CAYhYlZ435o4i8w3Bi96SxQCuXSjLPjx1Q3qcZLQlu6w9rCLNDo_AV_tYwz7qpRryDkOYf3PecUHFlnNQCPMZphhMj59RhmWFB8D5xgJFgmyrI82t05ywrM6TE4DeEaISQEZQ_AMcEcMcb5CfhWm3EaorLaTQEq28G1uVpnce3ddLXeTBHeTMpGE1U0zkLXw8kbq_wWRh29ss7Dy-XL6ofyl5dFBZstdHYwVsP6cpGt5llVn1c1VAEa2w9qHFV0yaYxblT-s_bhIbjfqyHoR4fzDHy8WHyYv8pW75ev5y9WWUtLjrOmIHnamXOMS8YUwph3ZU4oUlj0RS66llFCu6Irte4KIXKKG9I0vClaTjDN8zPwbO-78e5m0iHK0YRWD8M-BFlyigXOqUjk8_-SGBFSMo6LMqFPDujUjLqTG2_SWlv5M-kEPD0AKrRq6FNSrQl3XBqMEEru_my9C8Hr_hbBSO7KlqlsuSs7obM_0PbQU-rBDH8TZHvBFzPo7T-N5Zuq_p03Ieqvt3yqSzKe80J-ereUhM_fFhcieeTfAa7sx1A |
CitedBy_id | crossref_primary_10_1002_bmc_4102 crossref_primary_10_1161_JAHA_123_032835 crossref_primary_10_1111_all_14741 crossref_primary_10_1016_j_jpba_2015_02_011 crossref_primary_10_1166_jbn_2024_3807 crossref_primary_10_1016_j_freeradbiomed_2019_03_017 crossref_primary_10_1080_10408347_2022_2035210 crossref_primary_10_1194_jlr_D023739 crossref_primary_10_1096_fj_201802547R crossref_primary_10_3390_molecules23123275 crossref_primary_10_1002_jssc_201200056 crossref_primary_10_1002_rcm_6963 crossref_primary_10_1016_j_bbrc_2016_12_151 crossref_primary_10_1016_j_cca_2013_03_031 crossref_primary_10_1016_j_jchromb_2014_01_046 crossref_primary_10_1016_j_prostaglandins_2019_106361 crossref_primary_10_1155_2021_5591115 crossref_primary_10_1016_j_jpba_2016_06_017 crossref_primary_10_1016_j_plefa_2014_09_006 crossref_primary_10_4155_bio_2018_0173 crossref_primary_10_1111_all_12376 crossref_primary_10_3390_nu14071319 crossref_primary_10_1166_jbt_2022_3113 crossref_primary_10_3390_metabo11020106 crossref_primary_10_1183_13993003_01390_2016 crossref_primary_10_1038_s41598_017_17798_w |
Cites_doi | 10.1172/JCI27540 10.1016/0262-1746(87)90010-2 10.1016/j.cgh.2006.07.015 10.1016/j.molimm.2008.04.014 10.1016/S0083-6729(00)58022-4 10.1002/jps.2600620406 10.1158/1078-0432.CCR-05-0733 10.1016/0090-6980(89)90088-9 10.1016/0090-6980(76)90160-X 10.1016/j.ab.2004.08.019 10.1016/j.freeradbiomed.2009.10.047 10.1016/j.jchromb.2008.06.042 10.4049/jimmunol.179.5.2766 10.1016/j.jaci.2004.04.041 10.1074/jbc.M706839200 10.1016/S0022-3565(25)10713-1 |
ContentType | Journal Article |
Copyright | Copyright © 2011 John Wiley & Sons, Ltd. 2015 INIST-CNRS |
Copyright_xml | – notice: Copyright © 2011 John Wiley & Sons, Ltd. – notice: 2015 INIST-CNRS |
DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7SR 7U5 8BQ 8FD JG9 L7M 7X8 |
DOI | 10.1002/jms.1941 |
DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Engineered Materials Abstracts Solid State and Superconductivity Abstracts METADEX Technology Research Database Materials Research Database Advanced Technologies Database with Aerospace MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Materials Research Database Engineered Materials Abstracts Solid State and Superconductivity Abstracts Technology Research Database Advanced Technologies Database with Aerospace METADEX MEDLINE - Academic |
DatabaseTitleList | MEDLINE CrossRef MEDLINE - Academic Materials Research Database |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Chemistry |
EISSN | 1096-9888 |
EndPage | 711 |
ExternalDocumentID | 21706677 24332242 10_1002_jms_1941 JMS1941 ark_67375_WNG_27CK5F90_1 |
Genre | article Journal Article |
GroupedDBID | --- -~X .3N .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52U 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A03 AAESR AAEVG AAHBH AAHQN AAMMB AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABIJN ACAHQ ACBWZ ACCZN ACGFS ACIWK ACNCT ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADZMN AEFGJ AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFFNX AFFPM AFGKR AFRAH AFWVQ AFZJQ AGHNM AGQPQ AGXDD AGYGG AHBTC AHMBA AI. AIDQK AIDYY AITYG AIURR AJXKR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB AQPKS ASPBG ATUGU AUFTA AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMNLL BNHUX BROTX BRXPI BSCLL BY8 CS3 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRSTM DU5 EBD EBS EJD F00 F01 F04 F5P FEDTE G-S G.N GNP GODZA H.T H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRSTM MSFUL MSSTM MXFUL MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG P2P P2W P2X P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RNS ROL RX1 RYL SAMSI SUPJJ TN5 TUS UB1 UQL V2E VH1 W8V W99 WBFHL WBKPD WIB WIH WIK WJL WOHZO WQJ WRJ WXSBR WYISQ XG1 XPP XV2 ZCG ZZTAW ~02 ~IA ~KM ~WT AAHHS ACCFJ AEEZP AEQDE AEUQT AFPWT AIWBW AJBDE RWI WRC AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7SR 7U5 8BQ 8FD JG9 L7M 7X8 |
ID | FETCH-LOGICAL-c4871-b5230027711866a0117d83240a19f539dc6424d5d8eed599341b2bb7b5c721433 |
IEDL.DBID | DR2 |
ISSN | 1076-5174 1096-9888 |
IngestDate | Thu Sep 04 21:40:39 EDT 2025 Fri Sep 05 13:44:34 EDT 2025 Thu Apr 03 07:07:49 EDT 2025 Mon Jul 21 09:14:50 EDT 2025 Sun Sep 21 06:14:28 EDT 2025 Thu Apr 24 22:55:17 EDT 2025 Wed Jan 22 16:29:49 EST 2025 Tue Sep 09 05:29:33 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Keywords | Solid phase extraction Biological fluid Tandem mass spectrometry Chemical analysis Metabolite HPLC chromatography Biological marker Prostaglandin E2 Electrospray Chemical enrichment Sample preparation LC―MS/MS Bronchus disease Chronic obstructive pulmonary disease Obstructive pulmonary disease tetranor PGEM Quantitative analysis Trace analysis Human Urine Validation Healthy subject Coupled method Respiratory disease Elimination Patient Prostaglandin D2 PGD biomarker PGE Mass spectrometry COPD tetranor PGDM |
Language | English |
License | http://onlinelibrary.wiley.com/termsAndConditions#vor CC BY 4.0 Copyright © 2011 John Wiley & Sons, Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4871-b5230027711866a0117d83240a19f539dc6424d5d8eed599341b2bb7b5c721433 |
Notes | istex:6C142311C7F2E975E7EF223F12E670EB6CFEA2AA ArticleID:JMS1941 ark:/67375/WNG-27CK5F90-1 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
PMID | 21706677 |
PQID | 1022867158 |
PQPubID | 23500 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_874191349 proquest_miscellaneous_1022867158 pubmed_primary_21706677 pascalfrancis_primary_24332242 crossref_primary_10_1002_jms_1941 crossref_citationtrail_10_1002_jms_1941 wiley_primary_10_1002_jms_1941_JMS1941 istex_primary_ark_67375_WNG_27CK5F90_1 |
PublicationCentury | 2000 |
PublicationDate | July 2011 |
PublicationDateYYYYMMDD | 2011-07-01 |
PublicationDate_xml | – month: 07 year: 2011 text: July 2011 |
PublicationDecade | 2010 |
PublicationPlace | Chichester, UK |
PublicationPlace_xml | – name: Chichester, UK – name: Chichester – name: England |
PublicationTitle | Journal of mass spectrometry. |
PublicationTitleAlternate | J. Mass Spectrom |
PublicationYear | 2011 |
Publisher | John Wiley & Sons, Ltd Wiley |
Publisher_xml | – name: John Wiley & Sons, Ltd – name: Wiley |
References | Y. Cheng, M. Wang, Y. Yu, J. Lawson, C. D. Funk, G. A. Fitzgerald, Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J. Clin. Invest. 2006, 116, 1391. L. J. Murphey, M. K. Williams, S. C. Sanchez, L. M. Byrne, I. Csiki, J. A. Oates, D. H. Johnson, J. D. Morrow, Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal. Biochem. 2004, 334, 266. S. M. Jachak, PGE synthase inhibitors as an alternative to COX-2 inhibitors. Curr. Opin. Invest. Drugs 2007, 8, 411. D. C. Monkhouse, L. Van Campen, A. J. Aguiar, Kinetics of dehydration and isomerization of prostaglandins E1 and E2. J. Pharm. Sci. 1973, 62, 576. R. Vassallo, P. R. Kroening, J. Parambil, H. Kita, Nicotine and oxidative cigarette smoke constituents induce immune-modulatory and pro-inflammatory dendritic cell responses. Mol. Immunol. 2008, 45, 3321. W. L. Song, M. Wang, E. Ricciotti, S. Fries, Y. Yu, T. Grosser, M. Reilly, J. A. Lawson, G. A. FitzGerald, Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans. J. Biol. Chem. 2008, 283, 1179. Y. Urade, O. Hayaishi, Prostaglandin D synthase: structure and function. Vitam. Horm. 2000, 58, 89. C. C. Lin, I. T. Lee, Y. L. Yang, C. W. Lee, Y. R. Kou, C. M. Yang, Induction of COX-2/PGE(2)/IL-6 is crucial for cigarette smoke extract-induced airway inflammation: role of TLR4-dependent NADPH oxidase activation. Free Radic. Biol. Med. 2010, 48, 240. R. H. Pullen, J. A. Howell, J. W. Cox, High performance liquid chromatographic determination of thromboxane B2 in human serum as a methoxime-panacylester derivative. Prostaglandins Leukot. Med. 1987, 29, 205. J. R. Neale, B. J. Dean, Liquid chromatography-tandem mass spectrometric quantification of the dehydration product of tetranor PGE-M, the major urinary metabolite of prostaglandin E(2) in human urine. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2008, 871, 72. H. W. Seyberth, B. J. Sweetman, J. C. Frolich, J. A. Oates, Quantifications of the major urinary metabolite of the E prostaglandins by mass spectrometry: evaluation of the method's application to clinical studies. Prostaglandins 1976, 11, 381. Y. Chen, B. Perussia, K. S. Campbell, Prostaglandin D2 suppresses human NK cell function via signaling through D prostanoid receptor. J. Immunol. 2007, 179, 2766. C. C. Chan, S. Boyce, C. Brideau, A. W. Ford-Hutchinson, R. Gordon, D. Guay, R. G. Hill, C. S. Li, J. Mancini, M. Penneton, et al, Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J. Pharmacol. Exp. Ther. 1995, 274, 1531. N. D. Gross, J. O. Boyle, J. D. Morrow, M. K. Williams, C. S. Moskowitz, K. Subbaramaiah, A. J. Dannenberg, A. J. Duffield-Lillico, Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers. Clin. Cancer Res. 2005, 11, 6087. J. C. Johnson, C. R. Schmidt, M. J. Shrubsole, D. D. Billheimer, P. R. Joshi, J. D. Morrow, M. J. Heslin, M. K. Washington, R. M. Ness, W. Zheng, D. A. Schwartz, R. J. Coffey, R. D. Beauchamp, N. B. Merchant, Urine PGE-M: a metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. Clin. Gastroenterol. Hepatol. 2006, 4, 1358. J. D. Morrow, W. G. Parsons III, L. J. Roberts II, Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 1989, 38, 263. P. H. Howarth, A. J. Knox, Y. Amrani, O. Tliba, R. A. Panettieri Jr., M. Johnson, Synthetic responses in airway smooth muscle. J. Allergy Clin. Immunol. 2004, 114, S32. 2007; 179 1973; 62 2010; 48 2004; 114 2004; 334 1976; 11 2000; 58 2007; 8 2008; 45 2006; 4 2006; 116 2008; 871 1995; 274 1989; 38 2005; 11 2008; 283 1987; 29 Jachak S. M. (e_1_2_6_3_2) 2007; 8 e_1_2_6_8_2 e_1_2_6_7_2 e_1_2_6_18_2 Chan C. C. (e_1_2_6_6_2) 1995; 274 e_1_2_6_9_2 e_1_2_6_4_2 e_1_2_6_5_2 e_1_2_6_12_2 e_1_2_6_13_2 e_1_2_6_2_2 e_1_2_6_10_2 e_1_2_6_11_2 e_1_2_6_16_2 e_1_2_6_17_2 e_1_2_6_14_2 e_1_2_6_15_2 |
References_xml | – reference: J. C. Johnson, C. R. Schmidt, M. J. Shrubsole, D. D. Billheimer, P. R. Joshi, J. D. Morrow, M. J. Heslin, M. K. Washington, R. M. Ness, W. Zheng, D. A. Schwartz, R. J. Coffey, R. D. Beauchamp, N. B. Merchant, Urine PGE-M: a metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. Clin. Gastroenterol. Hepatol. 2006, 4, 1358. – reference: D. C. Monkhouse, L. Van Campen, A. J. Aguiar, Kinetics of dehydration and isomerization of prostaglandins E1 and E2. J. Pharm. Sci. 1973, 62, 576. – reference: R. H. Pullen, J. A. Howell, J. W. Cox, High performance liquid chromatographic determination of thromboxane B2 in human serum as a methoxime-panacylester derivative. Prostaglandins Leukot. Med. 1987, 29, 205. – reference: R. Vassallo, P. R. Kroening, J. Parambil, H. Kita, Nicotine and oxidative cigarette smoke constituents induce immune-modulatory and pro-inflammatory dendritic cell responses. Mol. Immunol. 2008, 45, 3321. – reference: S. M. Jachak, PGE synthase inhibitors as an alternative to COX-2 inhibitors. Curr. Opin. Invest. Drugs 2007, 8, 411. – reference: N. D. Gross, J. O. Boyle, J. D. Morrow, M. K. Williams, C. S. Moskowitz, K. Subbaramaiah, A. J. Dannenberg, A. J. Duffield-Lillico, Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers. Clin. Cancer Res. 2005, 11, 6087. – reference: Y. Urade, O. Hayaishi, Prostaglandin D synthase: structure and function. Vitam. Horm. 2000, 58, 89. – reference: C. C. Chan, S. Boyce, C. Brideau, A. W. Ford-Hutchinson, R. Gordon, D. Guay, R. G. Hill, C. S. Li, J. Mancini, M. Penneton, et al, Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J. Pharmacol. Exp. Ther. 1995, 274, 1531. – reference: L. J. Murphey, M. K. Williams, S. C. Sanchez, L. M. Byrne, I. Csiki, J. A. Oates, D. H. Johnson, J. D. Morrow, Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal. Biochem. 2004, 334, 266. – reference: C. C. Lin, I. T. Lee, Y. L. Yang, C. W. Lee, Y. R. Kou, C. M. Yang, Induction of COX-2/PGE(2)/IL-6 is crucial for cigarette smoke extract-induced airway inflammation: role of TLR4-dependent NADPH oxidase activation. Free Radic. Biol. Med. 2010, 48, 240. – reference: P. H. Howarth, A. J. Knox, Y. Amrani, O. Tliba, R. A. Panettieri Jr., M. Johnson, Synthetic responses in airway smooth muscle. J. Allergy Clin. Immunol. 2004, 114, S32. – reference: Y. Cheng, M. Wang, Y. Yu, J. Lawson, C. D. Funk, G. A. Fitzgerald, Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J. Clin. Invest. 2006, 116, 1391. – reference: J. R. Neale, B. J. Dean, Liquid chromatography-tandem mass spectrometric quantification of the dehydration product of tetranor PGE-M, the major urinary metabolite of prostaglandin E(2) in human urine. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2008, 871, 72. – reference: J. D. Morrow, W. G. Parsons III, L. J. Roberts II, Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 1989, 38, 263. – reference: W. L. Song, M. Wang, E. Ricciotti, S. Fries, Y. Yu, T. Grosser, M. Reilly, J. A. Lawson, G. A. FitzGerald, Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans. J. Biol. Chem. 2008, 283, 1179. – reference: Y. Chen, B. Perussia, K. S. Campbell, Prostaglandin D2 suppresses human NK cell function via signaling through D prostanoid receptor. J. Immunol. 2007, 179, 2766. – reference: H. W. Seyberth, B. J. Sweetman, J. C. Frolich, J. A. Oates, Quantifications of the major urinary metabolite of the E prostaglandins by mass spectrometry: evaluation of the method's application to clinical studies. Prostaglandins 1976, 11, 381. – volume: 274 start-page: 1531 year: 1995 article-title: Pharmacology of a selective cyclooxygenase‐2 inhibitor, L‐745,337: a novel nonsteroidal anti‐inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach publication-title: J. Pharmacol. Exp. Ther. – volume: 48 start-page: 240 year: 2010 article-title: Induction of COX‐2/PGE(2)/IL‐6 is crucial for cigarette smoke extract‐induced airway inflammation: role of TLR4‐dependent NADPH oxidase activation publication-title: Free Radic. Biol. Med. – volume: 116 start-page: 1391 year: 2006 article-title: Cyclooxygenases, microsomal prostaglandin E synthase‐1, and cardiovascular function publication-title: J. Clin. Invest. – volume: 8 start-page: 411 year: 2007 article-title: PGE synthase inhibitors as an alternative to COX‐2 inhibitors publication-title: Curr. Opin. Invest. Drugs – volume: 45 start-page: 3321 year: 2008 article-title: Nicotine and oxidative cigarette smoke constituents induce immune‐modulatory and pro‐inflammatory dendritic cell responses publication-title: Mol. Immunol. – volume: 334 start-page: 266 year: 2004 article-title: Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase‐specific PGE2 synthesis in healthy humans and those with lung cancer publication-title: Anal. Biochem. – volume: 11 start-page: 381 year: 1976 article-title: Quantifications of the major urinary metabolite of the E prostaglandins by mass spectrometry: evaluation of the method's application to clinical studies publication-title: Prostaglandins – volume: 11 start-page: 6087 year: 2005 article-title: Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers publication-title: Clin. Cancer Res. – volume: 179 start-page: 2766 year: 2007 article-title: Prostaglandin D2 suppresses human NK cell function via signaling through D prostanoid receptor publication-title: J. Immunol. – volume: 29 start-page: 205 year: 1987 article-title: High performance liquid chromatographic determination of thromboxane B2 in human serum as a methoxime‐panacylester derivative publication-title: Prostaglandins Leukot. Med. – volume: 58 start-page: 89 year: 2000 article-title: Prostaglandin D synthase: structure and function publication-title: Vitam. Horm. – volume: 62 start-page: 576 year: 1973 article-title: Kinetics of dehydration and isomerization of prostaglandins E1 and E2 publication-title: J. Pharm. Sci. – volume: 38 start-page: 263 year: 1989 article-title: Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid publication-title: Prostaglandins – volume: 283 start-page: 1179 year: 2008 article-title: Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans publication-title: J. Biol. Chem. – volume: 871 start-page: 72 year: 2008 article-title: Liquid chromatography‐tandem mass spectrometric quantification of the dehydration product of tetranor PGE‐M, the major urinary metabolite of prostaglandin E(2) in human urine publication-title: J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. – volume: 114 start-page: S32 year: 2004 article-title: Synthetic responses in airway smooth muscle publication-title: J. Allergy Clin. Immunol. – volume: 4 start-page: 1358 year: 2006 article-title: Urine PGE‐M: a metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia publication-title: Clin. Gastroenterol. Hepatol. – ident: e_1_2_6_11_2 doi: 10.1172/JCI27540 – ident: e_1_2_6_15_2 doi: 10.1016/0262-1746(87)90010-2 – ident: e_1_2_6_13_2 doi: 10.1016/j.cgh.2006.07.015 – volume: 8 start-page: 411 year: 2007 ident: e_1_2_6_3_2 article-title: PGE synthase inhibitors as an alternative to COX‐2 inhibitors publication-title: Curr. Opin. Invest. Drugs – ident: e_1_2_6_7_2 doi: 10.1016/j.molimm.2008.04.014 – ident: e_1_2_6_2_2 doi: 10.1016/S0083-6729(00)58022-4 – ident: e_1_2_6_10_2 doi: 10.1002/jps.2600620406 – ident: e_1_2_6_8_2 doi: 10.1158/1078-0432.CCR-05-0733 – ident: e_1_2_6_18_2 doi: 10.1016/0090-6980(89)90088-9 – ident: e_1_2_6_17_2 doi: 10.1016/0090-6980(76)90160-X – ident: e_1_2_6_12_2 doi: 10.1016/j.ab.2004.08.019 – ident: e_1_2_6_4_2 doi: 10.1016/j.freeradbiomed.2009.10.047 – ident: e_1_2_6_14_2 doi: 10.1016/j.jchromb.2008.06.042 – ident: e_1_2_6_16_2 doi: 10.4049/jimmunol.179.5.2766 – ident: e_1_2_6_5_2 doi: 10.1016/j.jaci.2004.04.041 – ident: e_1_2_6_9_2 doi: 10.1074/jbc.M706839200 – volume: 274 start-page: 1531 year: 1995 ident: e_1_2_6_6_2 article-title: Pharmacology of a selective cyclooxygenase‐2 inhibitor, L‐745,337: a novel nonsteroidal anti‐inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach publication-title: J. Pharmacol. Exp. Ther. doi: 10.1016/S0022-3565(25)10713-1 |
SSID | ssj0009946 |
Score | 2.1218693 |
Snippet | Quantitation of urinary tetranor PGDM or tetranor PGEM (tPGDM and tPGEM) in the past was performed separately using off‐line SPE LC–MS/MS methods. The manual... Quantitation of urinary tetranor PGDM or tetranor PGEM (tPGDM and tPGEM) in the past was performed separately using off-line SPE LC-MS/MS methods. The manual... |
SourceID | proquest pubmed pascalfrancis crossref wiley istex |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 705 |
SubjectTerms | Acceptability Assaying Biological and medical sciences biomarker Biomarkers - urine Chronic obstructive pulmonary disease, asthma COPD High-Throughput Screening Assays - methods Human Humans Inflammation - urine Investigative techniques, diagnostic techniques (general aspects) LC-MS/MS Least-Squares Analysis Mass spectrometry Medical sciences On-line systems Online Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques Patients PGD2 PGE2 Pneumology Prostaglandin D2 - analogs & derivatives Prostaglandin D2 - urine Prostaglandins - urine Pulmonary Disease, Chronic Obstructive - urine Reproducibility of Results Respiratory system Sensitivity and Specificity Smoking Solid Phase Extraction - methods Tandem Mass Spectrometry - methods tetranor PGDM tetranor PGEM Urine validation |
Title | Simultaneous and high-throughput quantitation of urinary tetranor PGDM and tetranor PGEM by online SPE-LC-MS/MS as inflammatory biomarkers |
URI | https://api.istex.fr/ark:/67375/WNG-27CK5F90-1/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjms.1941 https://www.ncbi.nlm.nih.gov/pubmed/21706677 https://www.proquest.com/docview/1022867158 https://www.proquest.com/docview/874191349 |
Volume | 46 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 1076-5174 databaseCode: DR2 dateStart: 19960101 customDbUrl: isFulltext: true eissn: 1096-9888 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009946 providerName: Wiley-Blackwell |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZQOcCF9yM8KiMhOGV3k9ib-IiW3VaFVBWhohIHy4-sxKPZskkk4NSfUIl_2F_CjJ3ssqiVEKdI0djx2ON4xv78DSHPjbUjkyYijBM2Dllc2lBpY0JlYP2zRljt2Pbz_fHuIds74kcdqhLvwnh-iNWGG84M97_GCa50PVyThn4-rgcQgWPkEyXcndC-WzNHCeEvFkGYHiIZc887O4qHfcGNlegqdup3REaqGjpn7rNaXOR2bnqxbhma3SQfewU8-uTLoG30wPz8i9vx_zS8RW503il95c3pNrlSVnfItUmfFO4uOSs-IQRRVeWiramqLEW-4_PTsy7fz0nb0G-tqpqO-psu5hT386ERtCkb0HexpAc7r3NX9o8305zqH9S3mhYHU6jy7eT89FdeDPOCqprCTADjPXagAIqkAYgrWtb3yOFs-n6yG3ZJHUIDsVEUatyGxoPjCKn2FFLS2QxZAVUk5jwR1kBExCy3GazeHLwnFulY61RzA8EqS5L7ZKtaVOVDRGVB7MhMBFWljEcQa4_nXI-YFiop04wF5GU_wNJ0amPija_SczXHEnpYYg8H5NlK8sSzfFwg88LZyEoA1ERUXMrlh_0dGaeTN3wmoFBAtjeMaFUgRq44cInga71VSRg-PKHxwyYx_EbCQZ4FhF4ik4EPiHAJEZAH3iLXH0AupHGaQlOdXV2qi9zLC3w--lfBx-S630xHnPITstUs2_IpeGON3nbz7jebjjLK |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDBaK9tBd9n54j04Dhu3kJH4otrDTkCbN2jgo5hbrYYCghwPsUaeLbWDbqT-hwP5hf8lIy06WoQWGnQwYlCxKpEVS1EdCXmpjejoKuOsHYd8N_cy4UmntSg37n9HcqBptP5n2x8fh_gk72SBv2rswFh9iGXBDzaj_16jgGJDurlBDP58WHXDBwfXZwuM51Mrd9yvsKM7t1SJw1F2EY26RZ3t-t225thdt4bR-x9xIWcD0zGxdi6sMz3U7tt6IRrfIx5YFm3_ypVOVqqN__oXu-J883iY3GwOVvrUSdYdsZPldsj1o68LdIxfpJ8xClHk2rwoqc0MR8vjy_KIp-XNWlfRbJfOyQf-m8xnFkD6MgpZZCQzPF_Rwbzep2_7xZphQ9YPaYdP0cAhdTgaX57-StJukVBYUlAHk97TOC6CIG4CpRYviPjkeDY8GY7ep6-BqcI88V2EkGs-OPUTbk4hKZ2IEBpQen7GAGw1OUWiYiWEDZ2BAhZ7ylYoU0-CvhkHwgGzm8zx7hIlZ4D6G2oOuIhABcLf7M6Z6oeIyyKI4dMjrdoWFbtjG2htfhYVr9gXMsMAZdsiLJeWZBfq4guZVLSRLAmATE-MiJj5M94QfDQ7YiEMjh-ysSdGygY9wcWAVwddasRKwfHhIY5dNoAeOmIMsdgi9hiYGMxAzJrhDHlqRXH0A4ZD6UQRDrQXrWl7EfpLi8_G_Ej4n2-OjZCIm76YHT8gNG1vHtOWnZLNcVNkzMM5KtVMr4W-gWzbm |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtNAEF2hVgJeuFPMpSwSgicnsb3ryyNKk5a2jiJMRSUerL3YErR1QmxLwFM_oRJ_2C9hxmsnBLUS4imSNWvv7M5m56yPzxDyWmk9UIEX2a7HfJu5mbaFVMoWCvY_rSItG7X9eOLvHbH9Y37csirxWxijD7E8cMOV0fxf4wKf67y_Eg39elb2AIED8tlkPoArTIg-rKSjosh8WQQ43UY15k54duD2u5ZrW9Emjup3pEaKEkYnN2Utrso719PYZh8a3yWfOw8M_eSkV1eyp37-Je74fy7eI3fa9JS-M_F0n9zIigfk1rCrCveQXCRfkIMoimxWl1QUmqLg8eX5RVvwZ15X9FstiqrV_qaznOKBPnSCVlkF_s4WdLq7Ezdt_7gyiqn8QU2vaTIdwS0Ph5fnv-KkHydUlBSWAkTvWcMKoKgagMSiRfmIHI1HH4d7dlvVwVYAjhxb4jk0vjl2UGtPoCadDlEWUDhRzr1IK4BETHMdwvbNIX1ijnSlDCRXgFaZ5z0mG8WsyJ4gLQvAI1MO3Cpg3AGw7edcDpiMhJcFIbPI226CU9W6jZU3TlMj1uymMMIpjrBFXi0t50bm4wqbN02MLA3ATaTFBTz9NNlN3WB4wMcRNLLI9loQLRu4KBYHORE8rYuqFKYPX9GYaUsRf6PiIA8tQq-xCSEJRL5EZJEtE5GrB6AYkh8E0NUmrq71Jd2PE_x9-q-GL8nN6c44PXw_OXhGbpuDdeQsPycb1aLOXkBmVsntZgn-BtrQNZU |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Simultaneous+and+high-throughput+quantitation+of+urinary+tetranor+PGDM+and+tetranor+PGEM+by+online+SPE-LC-MS%2FMS+as+inflammatory+biomarkers&rft.jtitle=Journal+of+mass+spectrometry.&rft.au=Zhang%2C+Yizhong&rft.au=Zhang%2C+Guodong&rft.au=Clarke%2C+Philip+A&rft.au=Huang%2C+Jeffrey+T+J&rft.date=2011-07-01&rft.issn=1096-9888&rft.eissn=1096-9888&rft.volume=46&rft.issue=7&rft.spage=705&rft_id=info:doi/10.1002%2Fjms.1941&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1076-5174&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1076-5174&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1076-5174&client=summon |